Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.

Prilocaine

Подписчиков: 0, рейтинг: 0
Prilocaine
Prilocaine.svg
Clinical data
Trade names Citanest
AHFS/Drugs.com Monograph
MedlinePlus a603026
License data
Pregnancy
category
  • AU: A
Routes of
administration
Subcutaneous
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding 55%
Metabolism Liver and kidney
Elimination half-life 10-150 minutes, longer with impaired liver or kidney function
Identifiers
  • (RS)-N-(2-methylphenyl)-N2-propylalaninamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.010.871
Chemical and physical data
Formula C13H20N2O
Molar mass 220.316 g·mol−1
3D model (JSmol)
Chirality Racemic mixture
Melting point 37 to 38 °C (99 to 100 °F)
  • O=C(Nc1ccccc1C)C(NCCC)C
  • InChI=1S/C13H20N2O/c1-4-9-14-11(3)13(16)15-12-8-6-5-7-10(12)2/h5-8,11,14H,4,9H2,1-3H3,(H,15,16) checkY
  • Key:MVFGUOIZUNYYSO-UHFFFAOYSA-N checkY
  (verify)

Prilocaine (/ˈprləˌkn/) is a local anesthetic of the amino amide type first prepared by Claes Tegner and Nils Löfgren. In its injectable form (trade name Citanest), it is often used in dentistry. It is also often combined with lidocaine as a topical preparation for dermal anesthesia (lidocaine/prilocaine or EMLA), for treatment of conditions like paresthesia. As it has low cardiac toxicity, it is commonly used for intravenous regional anaesthesia (IVRA).

Contraindications

In some patients, ortho-toluidine, a metabolite of prilocaine, may cause methemoglobinemia, which may be treated with methylene blue. Prilocaine may also be contraindicated in people with sickle cell anemia, anemia, or symptomatic hypoxia.

Combinations

It is given as a combination with the vasoconstrictor epinephrine under the trade name Citanest Forte. It is used as a eutectic mixture with lidocaine, 50% w/w, as lidocaine/prilocaine. The mixture is an oil with a melting point of 18 °C (64 °F). A 5% emulsion preparation, containing 2.5% each of lidocaine/prilocaine, is marketed by APP Pharmaceuticals under the trade name EMLA (an abbreviation for eutectic mixture of local anesthetics).

Compendial status

Synthesis

Synthesis: Patents: Revised: Sino:

The amidation between o-toluidine [95-53-4] (1) and 2-bromopropionyl bromide [563-76-8] (2) leads to 2-bromo-N-(2-methylphenyl)propanamide [19397-79-6] (3). Displacement of the remaining halide with propylamine [107-10-8] (4) completed the synthesis of prilocaine (5).

See also

External links


Новое сообщение